Janssen R&D Ireland Patent applications |
Patent application number | Title | Published |
20150239892 | Pyrrolo[3,2-]pyrimidine derivatives for the treatment of viral infections and other diseases - This invention concerns pyrrolo[3,2-d]pyrimidine derivatives, processes for their preparation, pharmaceutical compositions, and their use in treatment and/or therapy of diseases. | 08-27-2015 |
20150158862 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH HETEROCYCLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - The present invention is concerned with novel 4-substituted 1,3-dihydro-2H-benzimidazol-2-one derivatives substituted with heterocycles having formula (I) | 06-11-2015 |
20150141365 | URACYL SPIROOXETANE NUCLEOSIDES - The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R | 05-21-2015 |
20140255347 | Macrocyclic Inhibitors Of Hepatitis C Virus - Inhibitors of HCV replication of formula (I) | 09-11-2014 |
20140171499 | Pseudopolymorphic Forms Of A HIV Protease Inhibitor - New pseudopolymorphic forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl(1S,2R)-3-[[(4-aminophenyl)sulfonyl](isobutyl)amino]-1-benzyl-2-hydroxypropylcarbamate and processes for producing them are disclosed. | 06-19-2014 |
20140171451 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones - The present invention is related to novel compounds of formula (I) that inhibit the activity of the FabI enzyme which are therefore useful in the treatment of bacterial infections. It further relates to pharmaceutical compositions comprising these compounds, and chemical processes for preparing these compounds. | 06-19-2014 |
20140142070 | DARUNAVIR COMBINATION FORMULATIONS - This invention relates to solid oral dosage forms of the HIV inhibitor Darunavir and/or a pharmaceutically acceptable salt or solvate thereof, and combination formulations thereof. | 05-22-2014 |
20140127797 | MUTATIONAL PROFILE IN HIV-1 GAG CLEAVAGE SITE CORRELATED WITH PHENOTYPIC DRUG RESISTANCE - The invention concerns novel mutations or mutational profiles of HIV-1 protease cleavage sites (CS) in the Gag region correlated with a phenotype causing alterations in sensitivity to anti-HIV drugs. The present invention also relates to the use of genotypic characterization of a target population of HIV and the subsequent association, i.e., correlation, of this information to phenotypic interpretation in order to correlate virus mutational profiles with drug resistance. The invention further relates to methods of utilizing the mutational profiles of the invention in databases, drug development, i.e., drug design, and drug modification, therapy and treatment design and clinical management. | 05-08-2014 |
20140107172 | Benzimidazole-imidazole derivatives - Inhibitors of HCV replication of formula I | 04-17-2014 |
20140107101 | Macrocyclic Indole Derivatives Useful as Hepatitis C Virus Inhibitors - Inhibitors of HCV replication of formula (I) | 04-17-2014 |
20140073642 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES - This invention relates to quinazoline derivatives, processes for their preparation, pharmaceutical compositions, and their use in therapy of disorders in which the modulation of toll-like-receptors is involved. | 03-13-2014 |
20130324527 | IMIDAZOPYRIDINES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - A compound satisfying formula I, a prodrug, N-oxide, addition salt, quaternary amine, metal complex, or a stereochemically isomeric form thereof: | 12-05-2013 |
20130267556 | AZAINDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - Azaindoles having inhibitory activity on RSV replication and having the formula I | 10-10-2013 |
20130267555 | INDOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS - Indoles having inhibitory activity on RSV replication and having the formula I | 10-10-2013 |
20130267508 | BENZIMIDAZOLE RESPIRATORY SYNCYTIAL VIRUS INHIBITORS - Benzimidazoles having inhibitory activity on RSV replication and having the formula | 10-10-2013 |
20130123244 | Hetero-Bicyclic Derivatives as HCV Inhibitors - Inhibitors of HCV replication of formula I | 05-16-2013 |
20130102777 | PREPARATION OF 13-CYCLOHEXYL-3-METHOXY-6-[METHYL-(2--ETHYL)-CARBAMOYL]-7H-INDOLO-[2,1-a]- -[2]-BENZAZEPINE-10-CARBOXYLIC ACID - The present invention relates to an improved method for the preparation of 13-cyclohexyl-3-methoxy-6-[methyl-(2-{2-[methyl-(sulphamoyl)-amino]-ethoxy}-ethyl)-carbamoyl]-7H-indolo-[2,1-a]-[2]-benzazepine-10-carboxylic acid. The present invention also relates to a new compound, namely tert-butyl (methyl-{2-[2-(methylamino)-ethoxy]-ethyl}-sulphamoyl)-carbamate, used in this improved method. | 04-25-2013 |
20130035341 | MACROCYCLIC INTEGRASE INHIBITORS - Compound having formula I | 02-07-2013 |
20120310616 | COMPUTATION OF THE COMBINED POTENCY OF DRUG REGIMENS FROM FITTED OR IN VITRO DETERMINED DOSE-RESPONSE CURVES - A method is described that computes the combined potency of a drug regimen based on predicted or in vitro determined dose-response response curves of the individual drugs in a treatment regimen. This is instrumental in those diagnostic situations where different instances of biomolecule sequences or other biomarkers are associated with a different, but measurable or predictable shape of the dose-response curve of one or more of the regimen drugs, and where the response to the drug can be translated to a (surrogate) clinical endpoint. | 12-06-2012 |
20120277690 | DEGRADABLE REMOVABLE IMPLANT FOR THE SUSTAINED RELEASE OF AN ACTIVE COMPOUND - A degradable, removable, pharmaceutical implant for the sustained release of one or more drugs in a subject, wherein the pharmaceutical implant is composed of a tube comprising an outer wall made of a degradable polymer completely surrounding a cavity, wherein the outer wall has a plurality of openings and wherein the cavity contains one or more sets of micro-particles, which micro-particles contain an active agent or a combination of two or more active agents, and wherein the size of the microparticles is selected such that the majority of the microparticles cannot pass through the openings. | 11-01-2012 |
20120252695 | Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers alone - The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV. | 10-04-2012 |